NCT05638932View on ClinicalTrials.gov

Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments

CompletedOBSERVATIONAL
Enrollment

1,442

Participants

Timeline

Start Date

June 16, 2020

Primary Completion Date

September 25, 2023

Study Completion Date

September 25, 2023

Conditions
COVID-19
Interventions
DRUG

Initiation of IL6Ri (tocilizumab or sarilumab) versus JAKi (baricitinib or tofacitinib) added to systemic corticosteroids of interest (CSI)

Real world use of either IL6Ri (TCZ or SAR) or JAKi (BAR or TOF)

Trial Locations (1)

10001

Aetion, Inc., New York

All Listed Sponsors
lead

Aetion, Inc.

OTHER

NCT05638932 - Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments | Biotech Hunter | Biotech Hunter